ELVN vs. TGTX, OGN, SRRK, ALVO, RARE, ADMA, BHVN, VRNA, ACLX, and CRNX
Should you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include TG Therapeutics (TGTX), Organon & Co. (OGN), Scholar Rock (SRRK), Alvotech (ALVO), Ultragenyx Pharmaceutical (RARE), ADMA Biologics (ADMA), Biohaven (BHVN), Verona Pharma (VRNA), Arcellx (ACLX), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.
Enliven Therapeutics vs.
Enliven Therapeutics (NASDAQ:ELVN) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 29.2% of Enliven Therapeutics shares are held by insiders. Comparatively, 10.5% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
TG Therapeutics has higher revenue and earnings than Enliven Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.
Enliven Therapeutics currently has a consensus target price of $38.25, indicating a potential upside of 78.16%. TG Therapeutics has a consensus target price of $40.67, indicating a potential upside of 37.62%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enliven Therapeutics is more favorable than TG Therapeutics.
Enliven Therapeutics has a net margin of 0.00% compared to TG Therapeutics' net margin of -5.42%. TG Therapeutics' return on equity of -8.32% beat Enliven Therapeutics' return on equity.
Enliven Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500.
TG Therapeutics received 648 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 76.42% of users gave TG Therapeutics an outperform vote.
In the previous week, TG Therapeutics had 24 more articles in the media than Enliven Therapeutics. MarketBeat recorded 26 mentions for TG Therapeutics and 2 mentions for Enliven Therapeutics. TG Therapeutics' average media sentiment score of 0.72 beat Enliven Therapeutics' score of 0.24 indicating that TG Therapeutics is being referred to more favorably in the news media.
Summary
TG Therapeutics beats Enliven Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Enliven Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enliven Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ELVN) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ELVN Stock Alerts